Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
NCT05333003Active, not recruiting
- Sponsor
- Center for Addiction and Mental Health
- Start
- May 2022
- Primary completion
- Aug 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial in obesity comparing Semaglutide with Placebo (2 arms). Primary endpoint: Percentage change in body weight at 32 weeks. Started May 2022; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05333003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333003.